which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

A chemist a UAlbany and his son are looking to make a major breakthrough in the world of Alzheimer's prevention. They believe ...

In a recent breakthrough in Alzheimer’s research, scientists at Auburn University have discovered a new drug, troriluzole, ...

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for ...

Leqembi manufacturers Eisai and Biogen priced the drug ... FDA to help clinicians and patients make informed decisions about the risk of side effects,” says an expert from the Alzheimer’s ...

The first drug found to slow down Alzheimer’s is to be given the green light for use in Britain. Lecanemab, hailed by experts as “the beginning of the end” for the disease, has been found to ...

AC Immune said its partner Life Molecular Imaging received fast-track designation from the U.S. Food and Drug Administration ... conditions: Alzheimer's disease, progressive supranuclear palsy ...

The treatment involves infusions of a new Alzheimer’s drug, lecanemab ... according to the FDA. The disease affects memory, thinking skills and, eventually, the ability to carry out simple ...

The first drug found ... for Alzheimer’s. “It slows the disease. Slows it by about 25 to 30 per cent,” he said. “So, you know, maybe if in the old days you were going to get five years ...